Abstract

Hypertension (HT) is one of the most frequent comorbidities in asthma and may negatively affect disease control. This study aimed to compare the clinical characteristics of nonsteroidal anti-inflammatory drug–exacerbated respiratory disease (NERD) patients receiving biologics, with and without HT. This observational real-life study included 23 NERD patients treated with omalizumab or mepolizumab. Four (17%) were receiving omalizumab, and 19 (83%) were receiving mepolizumab. HT was present in five patients (22%). The median age was 43 years, and was higher in patients with HT. A family history of asthma was more frequent in hypertensive patients compared to those without HT. There was no significant difference between patients with and without HT in terms of asthma duration, duration of biological therapy, or asthma control. HT was present in approximately one-fifth of severe asthmatics with NERD receiving biological therapy. The coexistence of HT did not appear to adversely affect asthma control or treatment outcomes.

Key words: Asthma, hypertension, NERD, asthma control, omalizumab, mepolizumab